| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/10/2005 | WO2005012529A1 Plant producing hyaluronic acid |
| 02/10/2005 | WO2005012524A1 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer |
| 02/10/2005 | WO2005012485A2 Methods for treating diabetes and related disorders using pde10a inhibitors |
| 02/10/2005 | WO2005012364A2 Complex matrix for biomedical use |
| 02/10/2005 | WO2005012352A1 SOLUBLE HUMAN INTERLEUKIN 18 RECEPTOR-α, METHOD OF ASSAYING THE SAME, ASSAY KIT AND MEDICINAL COMPOSITION |
| 02/10/2005 | WO2005012326A1 Novel compounds having inhibitory activity against sodium-dependant transporter |
| 02/10/2005 | WO2005012318A2 Substituted fused heterocyclic c-glycosides |
| 02/10/2005 | WO2005012314A1 Process for controlling crystal structure of risedronate |
| 02/10/2005 | WO2005012309A1 Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
| 02/10/2005 | WO2005012305A2 Tricyclic parp inhibitors |
| 02/10/2005 | WO2005012294A1 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| 02/10/2005 | WO2005012293A1 Phenylazole compounds, production process, and antioxidants |
| 02/10/2005 | WO2005012289A1 Novel salt of (r) - pantoprazole |
| 02/10/2005 | WO2005012284A1 4,5-DIHYDRONAPHTHO[1,2-b]THIOPHENE DERIVATIVE |
| 02/10/2005 | WO2005012283A1 Substituted benzothiophene compounds and uses thereof |
| 02/10/2005 | WO2005012281A1 Neuroprotective benzo[1,3]oxathol-2-ones |
| 02/10/2005 | WO2005012280A1 Alkynyl aryl carboxamides |
| 02/10/2005 | WO2005012278A2 Process for purifying citalopram using polybasic acids |
| 02/10/2005 | WO2005012276A2 Intermediate products of the synthesis of fluorized inhibitors of aspartic proteases |
| 02/10/2005 | WO2005012275A2 Benzo [1, 2, 5] thiadiazole compounds as cck2 modulators |
| 02/10/2005 | WO2005012270A2 Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same |
| 02/10/2005 | WO2005012269A1 Novel azole compound |
| 02/10/2005 | WO2005012268A1 Sulfonamide derivative having isoxazole ring |
| 02/10/2005 | WO2005012263A1 5-ht2b receptor antagonists |
| 02/10/2005 | WO2005012259A1 Method of inhibiting production of osteopontin |
| 02/10/2005 | WO2005012255A1 Remedy for inflammatory joint diseases |
| 02/10/2005 | WO2005012248A1 Benzylamine derivative |
| 02/10/2005 | WO2005012245A1 Novel heteroaryl derivative |
| 02/10/2005 | WO2005012244A1 Substituted benzoylureido-o-benzoylamides, method for the production thereof and use of the same |
| 02/10/2005 | WO2005012243A2 Substituted indole-o-glucosides |
| 02/10/2005 | WO2005012242A2 Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides |
| 02/10/2005 | WO2005012234A1 Compounds for modulating cell proliferation |
| 02/10/2005 | WO2005012233A1 Meldonium salts, method of their preparation and pharmaceutical composition on their basis |
| 02/10/2005 | WO2005012226A1 Immunomodulation with novel pharmaceutical compositions |
| 02/10/2005 | WO2005012210A2 Antimicrobial active preparations containing terpene derivatives |
| 02/10/2005 | WO2005011813A2 Treatment of ocular disease |
| 02/10/2005 | WO2005011811A1 Carbostyril derivatives for accelerating salivation |
| 02/10/2005 | WO2005011752A1 Method of sterilization by irradiation of polymeric materials suitable for therapeutical purposes |
| 02/10/2005 | WO2005011741A2 Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle |
| 02/10/2005 | WO2005011737A2 Pharmaceutical combinations and formulations with improved stability |
| 02/10/2005 | WO2005011736A1 Drug for preventing and/or treating alzheimer’s disease |
| 02/10/2005 | WO2005011734A2 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer |
| 02/10/2005 | WO2005011727A1 Combination of an activator of soluble guanylate cyclase and an ace-inhibitor for the treatment of a cardiovascular or metabolic disorder |
| 02/10/2005 | WO2005011718A1 Antistress agent |
| 02/10/2005 | WO2005011712A1 Natural astaxanthin extract reduces dna oxidation |
| 02/10/2005 | WO2005011710A1 Per-6-aminosubstituted-deoxy-cyclodextrins to treat alzheimer’s diseases |
| 02/10/2005 | WO2005011709A1 Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections |
| 02/10/2005 | WO2005011708A1 Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers |
| 02/10/2005 | WO2005011707A1 A doxycycline metal complex in a solid dosage form |
| 02/10/2005 | WO2005011705A1 Enhancement of erectile function |
| 02/10/2005 | WO2005011704A1 Product containing prostaglandin |
| 02/10/2005 | WO2005011703A1 2-cyano-1,3,5-triazine-4,6-diamine derivatives |
| 02/10/2005 | WO2005011702A1 Process for preparing particles containing an antiviral |
| 02/10/2005 | WO2005011701A1 Use of quinazoline tyrosine kinase inhibitors in the treatment of inflammatory processes |
| 02/10/2005 | WO2005011700A1 INHIBITORS OF Akt ACTIVITY |
| 02/10/2005 | WO2005011699A1 Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| 02/10/2005 | WO2005011698A1 Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia |
| 02/10/2005 | WO2005011697A2 Sulfonamide derivatives with activity on protein kinase a and b |
| 02/10/2005 | WO2005011696A1 Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| 02/10/2005 | WO2005011695A1 Method of treating preeclampsia employing metolazone |
| 02/10/2005 | WO2005011693A1 Piperidine compounds useful as malonyl-coa decarboxylase inhibitors |
| 02/10/2005 | WO2005011692A1 Alkaline salts of proton pump inhibitors |
| 02/10/2005 | WO2005011691A1 Improved binding of pantoprazole to the proton pump |
| 02/10/2005 | WO2005011690A1 Use of 3,7-diazabicyclo`3, 3,1 !nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients |
| 02/10/2005 | WO2005011689A2 Treatment of inflamed joints |
| 02/10/2005 | WO2005011688A1 Cci-779 lyophilized formulations |
| 02/10/2005 | WO2005011687A1 Transdermaltherapeutic system containing a pramipexol active agent |
| 02/10/2005 | WO2005011685A1 Aryl dicarboxamides |
| 02/10/2005 | WO2005011684A1 Medicaments containing derivatives of aryl (or heteroaryl) azolylcarbinols |
| 02/10/2005 | WO2005011683A1 Transdermal absorption preparation |
| 02/10/2005 | WO2005011682A1 Sustained release tablet for oral use |
| 02/10/2005 | WO2005011681A1 Chemical compounds |
| 02/10/2005 | WO2005011680A1 Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |
| 02/10/2005 | WO2005011678A1 Method for reducing the volume of gastric refluxate |
| 02/10/2005 | WO2005011677A1 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
| 02/10/2005 | WO2005011676A1 Composition for the treatment of vitiligo |
| 02/10/2005 | WO2005011673A1 Use of antitumoral compounds |
| 02/10/2005 | WO2005011672A1 Processed fat composition for preventing/ameliorating lifestyle-related diseases |
| 02/10/2005 | WO2005011671A1 Use of flavonoids for preventing and treating gastritis and gastric ulcer |
| 02/10/2005 | WO2005011670A1 Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors |
| 02/10/2005 | WO2005011669A1 Medicinal composition for percutaneous administration |
| 02/10/2005 | WO2005011668A1 Methods of therapeutic treatment using amounts of retinoid components |
| 02/10/2005 | WO2005011667A1 Methods of therapeutic treatment using amounts of retinoid components |
| 02/10/2005 | WO2005011666A1 Stable sustained release oral dosage form of gabapentin |
| 02/10/2005 | WO2005011665A1 The use of proglumide for the treatment of emesis |
| 02/10/2005 | WO2005011663A1 Use of a biguanide derivative for protecting skin against uvb radiation |
| 02/10/2005 | WO2005011662A1 Adhesive patch |
| 02/10/2005 | WO2005011661A1 Pharmaceutical agents |
| 02/10/2005 | WO2005011660A1 Use of vitamin d to down regulate the renin-angiotensin-aldosterone system |
| 02/10/2005 | WO2005011659A1 Use of n-alkanols as activators of the cftr channel |
| 02/10/2005 | WO2005011658A2 Chroman-derivated anti-androgens for treatment of androgen-mediated disorders |
| 02/10/2005 | WO2005011657A2 Piperazine derivatives and their use as therapeutic agents |
| 02/10/2005 | WO2005011656A2 Pyridyl derivatives and their use as therapeutic agents |
| 02/10/2005 | WO2005011655A2 Pyridazine derivatives and their use as therapeutic agents |
| 02/10/2005 | WO2005011654A2 Pyridyl derivatives and their use as therapeutic agents |
| 02/10/2005 | WO2005011653A2 Pyridazine derivatives and their use as therapeutic agents |
| 02/10/2005 | WO2005011652A2 Use of a vitamin d receptor activator or a vitamin d analog to treat kidney disease |
| 02/10/2005 | WO2005011651A2 Use of a vitamin d receptor activator or a vitamin d analog to treat cardiovascular disease |
| 02/10/2005 | WO2005011650A1 Tranexamic acid formulations with reduced adverse effects |
| 02/10/2005 | WO2005011649A2 Methods of treating severe acute respiratory syndrome virus infections |